These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 24212823)

  • 1. State of the art in tumor antigen and biomarker discovery.
    Even-Desrumeaux K; Baty D; Chames P
    Cancers (Basel); 2011 Jun; 3(2):2554-96. PubMed ID: 24212823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy.
    Bracci L; Fragale A; Gabriele L; Moschella F
    Front Immunol; 2020; 11():582744. PubMed ID: 33193392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Biomarkers Discovery and Validation: State of the Art, Problems and Future Perspectives.
    Mordente A; Meucci E; Martorana GE; Silvestrini A
    Adv Exp Med Biol; 2015; 867():9-26. PubMed ID: 26530357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive biomarkers in clinical practice: State of the art and perspectives in solid tumors.
    Ulivi P
    Int J Biol Markers; 2020 Feb; 35(1_suppl):16-19. PubMed ID: 32079460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer biomarker discovery and translation: proteomics and beyond.
    Hristova VA; Chan DW
    Expert Rev Proteomics; 2019 Feb; 16(2):93-103. PubMed ID: 30556752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery.
    Nawaz M; Fatima F; Nazarenko I; Ekström K; Murtaza I; Anees M; Sultan A; Neder L; Camussi G; Valadi H; Squire JA; Kislinger T
    Expert Rev Proteomics; 2016; 13(4):395-409. PubMed ID: 26973172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
    Yuan J; Hegde PS; Clynes R; Foukas PG; Harari A; Kleen TO; Kvistborg P; Maccalli C; Maecker HT; Page DB; Robins H; Song W; Stack EC; Wang E; Whiteside TL; Zhao Y; Zwierzina H; Butterfield LH; Fox BA
    J Immunother Cancer; 2016; 4():3. PubMed ID: 26788324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating protein and antibody biomarker for personalized cancer immunotherapy.
    Yuan J
    J Immunother Cancer; 2016; 4():46. PubMed ID: 27532021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying biomarkers for predicting successful embryo implantation: applying single to multi-OMICs to improve reproductive outcomes.
    Hernández-Vargas P; Muñoz M; Domínguez F
    Hum Reprod Update; 2020 Feb; 26(2):264-301. PubMed ID: 32096829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers for the development of cancer vaccines: current status.
    Copier J; Whelan M; Dalgleish A
    Mol Diagn Ther; 2006; 10(6):337-43. PubMed ID: 17154650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in oral personalized medicine: contribution of 'omics'.
    Glurich I; Acharya A; Brilliant MH; Shukla SK
    J Oral Microbiol; 2015; 7():28223. PubMed ID: 26344171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in proteomic prostate cancer biomarker discovery.
    Goo YA; Goodlett DR
    J Proteomics; 2010 Sep; 73(10):1839-50. PubMed ID: 20398807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "
    Gemmati D; Varani K; Bramanti B; Piva R; Bonaccorsi G; Trentini A; Manfrinato MC; Tisato V; Carè A; Bellini T
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31906252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor antigen targets and tumor immunotherapy.
    Mufson RA
    Front Biosci; 2006 Jan; 11():337-43. PubMed ID: 16146735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy approaches for malignant glioma from 2007 to 2009.
    Johnson LA; Sampson JH
    Curr Neurol Neurosci Rep; 2010 Jul; 10(4):259-66. PubMed ID: 20424975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity in cancer immunotherapy.
    Schietinger A; Philip M; Schreiber H
    Semin Immunol; 2008 Oct; 20(5):276-85. PubMed ID: 18684640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy.
    Vonderheide RH; June CH
    Immunol Res; 2003; 27(2-3):341-56. PubMed ID: 12857980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in theranostic biomarkers for tumor immunotherapy.
    Bellesoeur A; Torossian N; Amigorena S; Romano E
    Curr Opin Chem Biol; 2020 Jun; 56():79-90. PubMed ID: 32217357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.